Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.65 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.65 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.65 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.65 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.65 |
| ▸ | GABRP | O00591 | 4/20 | 0.61 |
| ▸ | GABRD | O14764 | 4/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 4/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 4/20 | 0.61 |
| ▸ | GABRE | P78334 | 4/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 4/20 | 0.61 |
| ▸ | GABRG1 | Q8N1C3 | 4/20 | 0.61 |
| ▸ | GABRG3 | Q99928 | 4/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25186704 | 1.00 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15672787 | 1.00 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15412346 | 1.00 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL25189601 | 1.00 | GRIN1 (0.65) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15992717 | 0.91 | GRIN1 (0.54) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL25193007 | 0.88 | GRIN1 (0.50) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL25194108 | 0.88 | GRIN1 (0.50) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL15412131 | 0.88 | G6PD (0.64) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL21030708 | 0.88 | GRIN1 (0.51) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C | |
| SCHEMBL1550994 | 0.85 | GRIN2D (0.47) | GRIN1GRIN2BGRIN2DGRIN2AGRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10160783-B2 | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2018-12-25 | — | — | US | disclosed |
| US-20170355728-A9 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY | 2017-12-14 | — | — | US | disclosed |
| US-20170037079-A1 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | UNIV WASHINGTON (US) | 2017-02-09 | — | — | US | disclosed |
| US-9512170-B2 | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors | WASHINGTON UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-20140249120-A1 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | WASHINGTON UNIVERSITY (US) | 2014-09-04 | — | — | US | disclosed |
| EP-0701444-B1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | PURDUE PHARMA LTD (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-0701444-A1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | COCENSYS, INC. (US) | 1996-03-20 | — | — | EP | disclosed |
| WO-1994027608-A9 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | — | 1995-01-12 | — | — | WO | disclosed |
| WO-1994027608-A1 | METHODS AND COMPOSITIONS FOR INDUCING SLEEP | COCENSYS, INC. (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10160783-B2 | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors | GABRB3, GABRA3, GABRA4 | GRIN1 65/4885GRIN2B 50/4885GRIN2D 121/4885 |
| US-20170037079-A1 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRA3, GABRA4 | GRIN1 65/4885GRIN2B 50/4885GRIN2D 121/4885 |
| US-20140249120-A1 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRA3, GABRA4 | GRIN1 65/4885GRIN2B 50/4885GRIN2D 121/4885 |
| US-20170355728-A9 | NEUROACTIVE 13, 17-SUBSTITUTED STEROIDS AS MODULATORS FOR GABA TYPE-A RECEPTORS | GABRB3, GABRA3, GABRA4 | GRIN1 65/4885GRIN2B 50/4885GRIN2D 121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.